Ca13Mab-17, a Novel Anti-Cadherin-13 Monoclonal Antibody for Versatile Applications

Our plain-English summary of Ca13Mab-17, a Novel Anti-Cadherin-13 Monoclonal Antibody for Versatile Applications, by K. Shimizu, H. Suzuki, M.K. Kaneko, et al (Antibodies, 2026).

The study

• Authors: K. Shimizu, H. Suzuki, M.K. Kaneko, Y. Kato
• Journal: Antibodies
• Published: 2026;15(3)
• Cited by: 4 articles, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

Background/objectives: Cadherin-13 (CDH13), part of the cadherin family, is attached to the plasma membrane through glycosylphosphatidylinositol. CDH13 plays essential roles in the development of the neurological and vascular systems and is a risk factor for neural and cardiovascular diseases. CDH13 is expressed on the plasma membrane in both mature and uncleaved precursor forms with the prodomain. Although several anti-CDH13 monoclonal antibodies (mAbs) are available for basic research, there have been no reports of anti-CDH13 mAbs that can detect both the mature form and the uncleaved precursor in flow cytometry.

Methods: We developed novel anti-human CDH13 mAbs (named Ca13Mabs) using the mature form of CDH13-expressed cells as an antigen.

Results: Among Ca13Mabs, a clone, Ca13Mab-17 (IgG2b, κ) specifically recognized the mature and uncleaved precursor CDH13-overexpressed Chinese hamster ovary-K1 (CHO/CDH13) cells with no detectable cross-reactivity toward 21 other cadherins by flow cytometry. Ca13Mab-17 also detected endogenous CDH13 in human glioblastoma (LN229 and U87MG) and lung mesothelioma (NCI-H2052) cell lines. The dissociation constant (KD) value of Ca13Mab-17 for LN229 was estimated at 4.1 × 10-8 M. Furthermore, Ca13Mab-17 detected both the mature and uncleaved precursor CDH13 in Western blotting. It also identified new blood vessels and glioblastoma cells by immunohistochemistry.

Conclusions: Ca13Mab-17 is a versatile tool for detecting both mature and uncleaved precursor forms of CDH13 and has potential for tumor diagnosis and therapy.

In plain English

This laboratory study, from Tohoku University in Japan, described how the authors developed new mouse monoclonal antibodies against a cell-surface protein called cadherin-13 (CDH13). It did not study asbestos exposure or asbestos-exposed people. Its only link to asbestos topics is that one cell line tested, NCI-H2052, is a human mesothelioma cell line. The authors immunized two mice with glioblastoma (brain tumor) cells engineered to carry the mature form of CDH13. They established 43 antibody-producing clones and selected one, Ca13Mab-17. In flow cytometry, Ca13Mab-17 bound cells engineered to carry CDH13 but not unaltered cells, and it did not react with cells carrying any of 21 other cadherins. It detected CDH13 naturally present in two glioblastoma cell lines and in the mesothelioma cell line. Its measured binding strength was moderate and weaker than that of a commercial antibody. It also detected CDH13 in Western blotting and in stained tissue, including blood vessels in glioblastoma samples. The authors concluded it is a versatile tool with potential for tumor diagnosis and therapy. They noted that the exact site where it binds still needs to be identified.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Laboratory study developing and testing monoclonal antibodies (mouse immunization, hybridoma production, flow cytometry, Western blotting, immunohistochemistry)
• Who was studied: Cell lines: CHO-K1 and engineered CHO-K1 cells, human glioblastoma lines LN229 and U87MG, and the human mesothelioma line NCI-H2052. Two female BALB/cAJcl mice were immunized. A glioblastoma tissue microarray (GL806e) and a colorectal cancer tissue microarray (CO483b) were stained.
• Exposure: No asbestos or other environmental exposure was studied. The 'exposure' was immunization of mice with LN229 glioblastoma cells engineered to express the mature form of CDH13, followed by testing of the resulting antibody.
• Main results:
  • 43 clones producing anti-CDH13 antibodies were established. Ca13Mab-17 (IgG2b, kappa) was selected because it worked in all applications tested.
  • In flow cytometry, Ca13Mab-17 bound CHO/CDH13 cells in a dose-dependent manner from 10 to 0.01 µg/mL. It did not recognize parental CHO-K1 cells even at 10 µg/mL.
  • Ca13Mab-17 recognized CHO/CDH13 but did not react with CHO-K1 cells overexpressing the other cadherins tested (21, per the authors' discussion).
  • Both Ca13Mab-17 and the commercial antibody 392411 detected naturally present CDH13 in LN229, U87MG and NCI-H2052 (mesothelioma) cells. At 10 and 1 µg/mL the two antibodies reacted similarly. At 0.1 and 0.01 µg/mL, 392411 showed higher reactivity.
  • Binding strength measured on LN229 cells: the dissociation constant was 4.1 (plus or minus 0.9) times 10 to the minus 8 molar for Ca13Mab-17, and 1.9 (plus or minus 0.8) times 10 to the minus 10 molar for 392411. The authors described Ca13Mab-17's affinity as moderate.
  • In Western blotting, Ca13Mab-17 detected a main band around 100 kDa in CHO/CDH13 lysates and no band in CHO-K1. It detected endogenous CDH13 in LN229 and U87MG at 110 and 130 kDa.
  • In a glioblastoma tissue microarray, Ca13Mab-17 stained tubular structures strongly and glioblastoma tissue moderately. Some cases had positive tubular structures with negative tumor.
  • In a colorectal cancer microarray, Ca13Mab-17 did not stain the colorectal cancers. It preferentially stained podoplanin-negative blood vessels and did not stain large podoplanin-positive lymphatic vessels.
• The authors' conclusion: The authors concluded that Ca13Mab-17 is a versatile tool for detecting both the mature and uncleaved precursor forms of CDH13, with potential for tumor diagnosis and therapy.
• Limitations the authors state:
  • The binding site (epitope) of Ca13Mab-17 has not yet been identified.
  • Further double-staining is needed to prove that CDH13 and podoplanin mark blood vessel and lymphatic endothelial cells exclusively.
  • The commercial antibody 392411 showed higher reactivity and affinity than Ca13Mab-17 on cancer cells with naturally present CDH13.

Topics

Medical terms in this study, explained in our Lexicon: Monoclonal Antibody, Mesothelioma, Immunohistochemistry.

Related studies

• Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection — A. Gupta, Z. Hussein, et al. (2016)
• Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model — S. Abe, M.K. Kaneko, et al. (2016)
• Medical application of the monoclonal antibody SKM9-2 against sialylated HEG1, a new precision marker for malignant mesothelioma — S. Tsuji, K. Imai (2023)
• Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy — R. Hassan, C. Schweizer, et al. (2010)
• A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition — M. Hayashi, H. Madokoro, et al. (2016)
• Localization of CD26/DPPIV in nucleus and its nuclear translocation enhanced by anti-CD26 monoclonal antibody with anti-tumor effect — K. Yamada, M. Hayashi, et al. (2009)

Browse return to medical research.